Display options
Cite
Pinheiro SP, Gates MA, De Vivo I, et al. Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet. 2010;1(4):320-31
Pinheiro, S. P., Gates, M. A., De Vivo, I., Rosner, B. A., Tworoger, S. S., Titus-Ernstoff, L., Hankinson, S. E., & Cramer, D. W. (2010). Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. International journal of molecular epidemiology and genetics, 1(4), 320-31.
Pinheiro, Simone P, et al. "Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk." International journal of molecular epidemiology and genetics vol. 1,4 (2010): 320-31.
Pinheiro SP, Gates MA, De Vivo I, Rosner BA, Tworoger SS, Titus-Ernstoff L, Hankinson SE, Cramer DW. Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk. Int J Mol Epidemiol Genet. 2010 Sep 03;1(4):320-31. PMID: 21532843; PMCID: PMC3076777.
Copy Download .nbib Format: NLM
Share it on

Int J Mol Epidemiol Genet. 2010 Sep 03;1(4):320-31.

Interaction between use of non-steroidal anti-inflammatory drugs and selected genetic polymorphisms in ovarian cancer risk.

International journal of molecular epidemiology and genetics

Simone P Pinheiro, Margaret A Gates, Immaculata De Vivo, Bernard A Rosner, Shelley S Tworoger, Linda Titus-Ernstoff, Susan E Hankinson, Daniel W Cramer

PMID: 21532843 PMCID: PMC3076777

Abstract

Inflammation and non-steroidal anti-inflammatory agents (NSAIDs) may play important role in ovarian cancer. However, epidemiologic data are inconsistent, possibly reflecting inter-individual genetic differences affecting the metabolism of NSAIDs. We examined whether common polymorphisms affecting the metabolism of NSAIDs modify the association between NSAIDs and ovarian cancer risk. We genotyped 1,353 DNA samples from women who developed ovarian cancer and 1,823 samples from matched controls participating in the New England Case-Control study and the Nurses' Health Studies. Conditional logistic regression estimated odds ratios (ORs) and 95% confidence intervals (CIs) associated with regular use of NSAIDs and with relevant polymorphisms on ovarian cancer risk. Multivariable unconditional logistic regression estimated the association of NSAID use across stratum of each genotype. Regular use of NSAIDs was not associated with ovarian cancer risk. Multivariable OR (95% CI) associated with use NSAIDs was 0.85 (95% CI: 0.71-1.02). Associations between NSAID use and ovarian cancer risk did not differ significantly across strata of genotypes. None of the studied polymorphisms was associated with ovarian cancer risk. The multivariable ORs (95% CI) associated with CYP2C9 and UGT1A6 variant genotypes were 0.99 (0.90-1.08) and 0.93 (0.82-1.05), respectively. The multivariable ORs (95% CI) associated with PPAR-γ, COX-2 -765G>C, and COX-2 Ex10+837T>C polymorphisms were 1.02 (0.87-1.20), 0.87 (0.75-1.00), and 0.97 (0.87-1.09), respectively. In this relatively large study, we found no convincing evidence supporting an association between NSAIDs use and ovarian cancer risk. Furthermore, data did not suggest interaction between selected polymorphisms and use of NSAIDs in relation to ovarian cancer risk.

Keywords: COX; CYP2C9; Non-steroidal anti-inflammatory drugs; PPAR-γ; UGT1A6; interaction; ovarian cancer; pharmacogenetics; polymorphism

References

  1. Cancer Epidemiol Biomarkers Prev. 2000 Sep;9(9):933-7 - PubMed
  2. Mol Genet Metab. 2004 Sep-Oct;83(1-2):93-102 - PubMed
  3. Cancer. 2008 Mar 1;112(5):1169-77 - PubMed
  4. J Natl Cancer Inst. 1998 Aug 5;90(15):1155-60 - PubMed
  5. Curr Top Med Chem. 2004;4(16):1733-44 - PubMed
  6. Br J Clin Pharmacol. 2006 Jul;62(1):113-21 - PubMed
  7. Cancer Epidemiol Biomarkers Prev. 2001 Aug;10(8):903-6 - PubMed
  8. Oncology. 2005;69 Suppl 1:28-32 - PubMed
  9. Clin Pharmacol Ther. 2005 Jan;77(1):1-16 - PubMed
  10. Drug Metab Dispos. 2005 Nov;33(11):1567-75 - PubMed
  11. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  12. Carcinogenesis. 2005 Mar;26(3):579-85 - PubMed
  13. Curr Opin Obstet Gynecol. 2005 Feb;17(1):49-53 - PubMed
  14. Cancer Res. 2006 Feb 15;66(4):2476-82 - PubMed
  15. Breast Cancer Res. 2006;8(6):R71 - PubMed
  16. Cancer Res. 2003 Jul 1;63(13):3560-6 - PubMed
  17. J Clin Oncol. 2005 Apr 20;23(12):2840-55 - PubMed
  18. Biochem Biophys Res Commun. 2000 Feb 5;268(1):178-82 - PubMed
  19. Cancer Epidemiol Biomarkers Prev. 2008 Sep;17(9):2436-44 - PubMed
  20. Am J Med. 1998 May;104(5):413-21 - PubMed
  21. J Natl Cancer Inst. 1999 Sep 1;91(17):1459-67 - PubMed
  22. Arterioscler Thromb Vasc Biol. 2002 Oct 1;22(10):1631-6 - PubMed
  23. Annu Rev Pharmacol Toxicol. 1998;38:97-120 - PubMed
  24. Pharmacogenetics. 1997 Dec;7(6):485-95 - PubMed
  25. J Natl Cancer Inst. 1998 Sep 2;90(17):1292-9 - PubMed
  26. Br J Clin Pharmacol. 1998 Jun;45(6):525-38 - PubMed
  27. Mol Pharmacol. 2007 Nov;72(5):1280-8 - PubMed
  28. J Natl Cancer Inst. 2005 Mar 16;97(6):457-60 - PubMed
  29. Genetics. 1964 Jan;49(1):49-67 - PubMed
  30. Semin Arthritis Rheum. 1997 Jun;26(6 Suppl 1):2-10 - PubMed
  31. Hypertension. 2005 Sep;46(3):500-7 - PubMed
  32. Cancer. 2007 Aug 15;110(4):791-800 - PubMed
  33. Br J Cancer. 2004 Aug 16;91(4):633-8 - PubMed
  34. Thromb Res. 2003 Jun 15;110(5-6):255-8 - PubMed
  35. Cancer Causes Control. 2002 Aug;13(6):535-42 - PubMed
  36. J Natl Cancer Inst. 1999 Jun 2;91(11):916-32 - PubMed
  37. Lancet. 1998 Jan 10;351(9096):104-7 - PubMed
  38. Annu Rev Biochem. 2000;69:145-82 - PubMed
  39. Subcell Biochem. 2007;42:93-126 - PubMed
  40. Nature. 2005 Oct 27;437(7063):1299-320 - PubMed
  41. Clin Pharmacol Ther. 2002 Nov;72(5):562-71 - PubMed
  42. Clin Gastroenterol Hepatol. 2006 Jul;4(7):894-901 - PubMed
  43. Pharmacogenetics. 2000 Mar;10(2):95-104 - PubMed
  44. Prev Med. 2001 Dec;33(6):682-7 - PubMed
  45. Am J Pharmacogenomics. 2003;3(1):37-52 - PubMed
  46. J Allergy Clin Immunol. 2005 Jul;116(1):221-3 - PubMed
  47. Int J Cancer. 2002 Jan 1;97(1):96-101 - PubMed
  48. Int J Cancer. 2008 Jan 1;122(1):170-6 - PubMed
  49. Br J Cancer. 2003 Jun 2;88(11):1687-92 - PubMed
  50. Arch Intern Med. 2004 Jul 26;164(14):1519-24 - PubMed
  51. J Biol Chem. 1997 Feb 7;272(6):3406-10 - PubMed
  52. Int J Cancer. 2004 Jan 10;108(2):281-6 - PubMed
  53. Int J Cancer. 2007 Dec 1;121(11):2373-80 - PubMed
  54. Chem Res Toxicol. 1995 Jan-Feb;8(1):136-42 - PubMed
  55. Pharmacotherapy. 2002 Mar;22(3):303-9 - PubMed
  56. Cancer Epidemiol Biomarkers Prev. 2005 Mar;14(3):616-9 - PubMed
  57. FASEB J. 2001 Oct;15(12):2057-72 - PubMed
  58. J Womens Health. 1997 Feb;6(1):49-62 - PubMed
  59. Br J Cancer. 2003 Mar 10;88(5):684-8 - PubMed
  60. Epidemiology. 2006 Jan;17(1):104-7 - PubMed
  61. Drug Metab Dispos. 2005 Jul;33(7):1027-35 - PubMed
  62. J Clin Pharmacol. 1997 Apr;37(4):267-78 - PubMed
  63. JAMA. 1993 Dec 15;270(23):2813-8 - PubMed
  64. Ann Oncol. 2000 Sep;11(9):1171-3 - PubMed
  65. Cancer Res. 2005 Jul 1;65(13):5974-81 - PubMed
  66. Cancer Res. 2001 May 1;61(9):3566-9 - PubMed

Publication Types

Grant support